Introduction
Angiotensin II (AngII), the main peptide of the renin-angiotensin system (RAS), is involved in the pathogenesis of renal diseases [1, 2] . This peptide acts through its binding to two specific receptors, AT 1 and AT 2 [2] . AT 1 is responsible for most of the pathophysiological actions of AngII. By promoting proliferation, inflammation and fibrosis, AngII contributes to chronic diseases, such as hypertension, atherosclerosis, cardiac hypertrophy and renal injury, The role of the AT 2 receptor is not completely defined.
AT 2 is involved in cell growth inhibition and inflammatory cell recruitment in the kidney [2] [3] [4] . We will review here the information regarding the novel mechanisms involved in the fibrotic and inflammatory response caused by AngII.
AngII regulates fibrosis via the AT1 receptor: role of CTGF and the Smad signalling pathway
AngII via AT 1 regulates extracellular matrix (ECM) accumulation mediated by the endogenous production of profibrotic growth factors, such as transforming growth factor-b (TGF-b). Angiotensin-converting enzyme (ACE) inhibitors and AT 1 antagonists decrease tissue expression of TGF-b and fibrosis; furthermore, blockade of TGF-b diminishes AngII-induced ECM production [2, 3] . Although TGF-b is one of the main regulators of fibrosis, therapeutic strategies blocking TGF-b actions have not afforded the expected beneficial effects probably because of its anti-inflammatory properties [5] . This is one of the reasons why novel antifibrotic targets are under active investigation. Connective tissue growth factor (CTGF) is a novel profibrotic factor that is upregulated in different human kidney diseases and contributes to renal fibrosis and tubuloepithelial transdifferentiation [6] . In models of renal injury, ACE inhibitors and AT 1 antagonists diminished CTGF upregulation and fibrosis [7, 8] . We have also demonstrated that the blockade of CTGF, by an antisense CTGF oligonucleotide, diminished AngII-induced fibrosis, shown by diminution of fibronectin production [7, 9] . These results suggest that CTGF could be a novel antifibrotic target ( Figure 1 ). The Smad proteins are essential components of the intracellular signalling pathways, acting as transcription factors of TGF-b-mediated responses, including fibrosis [10] . We have recently shown that AngII via AT 1 activates the Smad signalling system, independently of TGF-b [11] . In vascular smooth muscle cells (VSMCs), AngII caused a rapid and direct activation of Smad2 phosphorylation, nuclear translocation of phosphorylated Smad2 and Smad4, increased DNAbinding activity and Smad-dependent gene transcription. In AngII-infused rats, aortic Smad overexpression was associated with CTGF induction and occurred before ECM accumulation [11] . Smad7 may function as a general negative regulator of TGF-b receptor signalling [12] . Transient transfection with Smad7, which interferes with receptor-mediated activation of Smad2 and Smad3, diminished CTGF, fibronectin and type 1 procollagen upregulation caused by AngII [11] . Moreover, Smad7 overexpression blocks TGF-b-induced ECM production and renal fibrosis [13] [14] [15] . AT 1 blockade diminishes Smad pathway activation and fibrosis in the model of renal injury caused by unilateral ureteral obstruction (UUO), in myocardial infarction in rats and in the aorta of AngII-infused rats [11, 16, 17] . These data indicate that Smad signalling could be a common mechanism of AngII-mediated fibrosis in cardiovascular and renal diseases and that the blockade of Smad activation could be another important anti-fibrotic target (Figure 1 ).
The small G protein Rho and AngII responses
The AT 1 are G-coupled receptors and activate small G proteins, including RhoA and the Rho kinase system [18] . The Rho/Rho kinase signalling pathway participates in the development of fibrotic lesions in several tissues including the kidney. In different experimental models, such as hypertensive glomerulosclerosis, UUO, nephrectomized spontaneously hypertensive rats and L-NAME-treated rats, administration of Rho kinase inhibitors diminished glomerular and tubulointerstitial injury, inflammation and fibrosis, and downregulated smooth muscle a-actin gene overexpression, as well as the TGF-b and ECM proteins [19] [20] [21] [22] [23] [24] . In rats infused with AngII, we have shown that the Rho kinase inhibitor Y-27632 diminished tubular damage, the number of inflammatory cells, and renal overexpression of CTGF and proinflammatory parameters [25] . All these data suggest that Rho kinase inhibitors could be novel targets for renal therapy (Figure 1 ).
AngII and the inflammatory response: role of AngII receptors and the NF-B pathway
AngII contributes to the recruitment of infiltrating cells into the kidney; AngII causes the adhesion of circulating cells to endothelial and mesangial cells, and the migration of inflammatory cells into the kidney. This process is mediated by upregulation of adhesion molecules, cytokines and chemokines [1] .
ACE inhibitors have been shown to diminish inflammatory cell infiltration and inflammatory markers in many animal models of renal injury [1] . AngII via AT 1 receptors upregulates many proinflammatory genes, such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1), through the activation of several intracellular signalling systems, including the nuclear factor-B (NF-B), mitogen-activated protein kinase (MAPK) cascade, Rho proteins and redox pathways [1] . Some experimental data suggest that AT 2 receptors are involved in the inflammatory cell recruitment in the kidney. Only AT 2 , but not AT 1 , antagonists diminished the number of inflammatory cells in different animal models, including systemic infusion of AngII and UUO [3, 4, 8, 26, 27] . We have recently demonstrated that combined treatment with AT 1 and AT 2 antagonists blocked the inflammatory response, and lowered the number of infiltrating cells and the overexpression of proinflammatory genes to control levels in those models [8, 27] . In the UUO model, AT 2 blockade diminished tumour necrosis factor-a (TNF-a) and RANTES overexpression, and the simultaneous blockade of both receptors abolished MCP-1 gene upregulation [8] . NF-B activation has been described in kidney diseases [1] . In vivo, AngII activates the renal NF-B pathway that was partially diminished by AT 1 or AT 2 antagonists alone, and was abolished by combination of both receptor antagonists or ACE inhibition [4, 8, 27] . In mesangial cells, NF-B activation was mediated by both AT 1 and AT 2 receptors [4] ; in tubuloepithelial cells, this was mainly by AT 1 [4] , while in endothelial cells it was via AT 2 [28] . In the UUO model, we have found that blockade of renal NF-B activation by treatment with two different NF-B inhibitors, pyrrolidine dithiocarbamate (PDTC) and parthenolide, diminished the inflammatory cell infiltration and downregulated gene expression of several proinflammatory factors [8] . In spontaneously hypertensive rats, NF-B inhibition attenuated renal interstitial inflammation and hypertension [29] . These data suggest that in some experimental renal diseases, the blockade of AngII generation by an ACE inhibitor or by combined blockade of both AT 1 and AT 2 receptors, as well as by the inhibition of the NF-B pathway, is necessary to stop the inflammatory process fully (Figure 2) .
In human kidney diseases, the activated renal renin-angiotensin system has been described. In diabetic nephropathy, elevated AngII generation did correlate with the presence of inflammatory cell infiltration, the activation of NF-B and proinflammatory gene overexpression [30] . These observations emphasize the importance of treatments that block the AngII-induced inflammatory process in human renal diseases.
Conclusion
Drugs that modulate the renin-angiotensin system, such as ACE inhibitors and AT 1 antagonists, have demonstrated protective renal effects and can ameliorate fibrosis. Current strategies in clinical practice combine treatments with ACE inhibitors and AT 1 blockers, due to their potential additive beneficial effects [31] . However, these treatments did not cause regression of renal damage, suggesting that novel approaches are needed. The data presented here highlight potential interesting candidates for antifibrotic treatments, including CTGF, the Smad signalling system and the Rho/Rho kinase pathway. Future studies are necessary to evaluate their potential beneficial effects fully in kidney diseases.
The Ang receptor subtype, AT 1 or AT 2 , involved in the inflammatory response in the kidney is not completely elucidated. Our results show that the blockade of both AT 1 and AT 2 receptors is necessary to stop the inflammatory process completely, at least in experimental models. The inhibition of the NF-B pathway also prevents inflammation and experimental renal damage. All these experimental studies provide a rationale to investigate further the involvement of the AT 2 /NF-B pathway in the inflammatory response in kidney diseases. These results could have potential clinical consequences in the treatment of severe human nephritis. 
